Delphia Therapeutics
Michael D. has extensive experience in the pharmaceutical and biotechnology sectors, currently serving as Chief Technology Officer at CuraSen Therapeutics, Inc. and Co-Founder of Delphia Therapeutics. Michael's previous roles include Associate at Crow Consulting, Chief Scientific Officer and Head of Research at IDEAYA Biosciences, and Global Head Oncology at Novartis Institutes for BioMedical Research. With a career that began as a Research Scientist at Roche Pharmaceuticals, Michael has held various leadership positions, contributing significantly to drug discovery and development, particularly in oncology. Michael holds a Ph.D. from the University of Bristol and a B.Sc. from the University of Leicester.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.